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Abstract
Objective: Children are ½ of the world’s refugees and often have intestinal parasites. This study
seeks to determine the intestinal burden and pre-departure treatment of Kentucky pediatric refugees.
Methods: This is a chart review of Kentucky pediatric refugee health screening data from 20122017. Stool culture results from children arriving through refugee camps were compared to noncamp children. They were placed into 3 regional groups and analyzed based on CDC pre-departure
treatment recommendations.
Results: Of the 3,199 records, 1,653 had stool testing. 354 (51%) refugee camp children tested
positive compared to 326 (33.9%) non-camp children. Giardia and Blastocystis were most commonly
identified. Treatment aligned with CDC guidelines 64.7% of the time. CDC compliance was 83%,
79.8%, and 30.2% from Regions 1, 2, and 3 respectively.
Discussion: Pre-departure treatment of pediatric refugees needs improved compliance with CDC
recommendations through education of refugee camp workers. Giardia and Blastocystis are common
and metronidazole is recommended for symptomatic children.

Background
Historically, the United States has resettled more than 50,000
refugees per year, half of whom are under 18 [1-3]. Although
this number has decreased significantly over the past two years,
refugees continue to arrive from either their country of origin or
a refugee camp in another country, typically in the same region
of the world as their country of origin. The state of Kentucky
has resettled over 15,000 refugees since 2012 [1]. The most
common countries of origin for refugees entering Kentucky
over the last several years have been Cuba, Iraq, Somalia,
Burma/Myanmar, Democratic Republic of Congo, and BhutanNepal [1]. Refugee populations are a vulnerable and medically
disenfranchised group in both their countries of origin and
resettlement. As no centralized database for the collection and
storage of refugee health data exists, individual states are tasked
with the development and maintenance of refugee health data at
the time of resettlement. The Kentucky Office for Refugees and
the University of Louisville Global Health Center work together
to perform the domestic health screenings of Kentucky’s newly
arrived refugees.
The Centers for Disease Control and Prevention (CDC)
oversees mandated health screenings in accordance with the
Refugee Act of 1980 [4]. At least 1/3 of the world’s population
is infected with parasites, making this a common condition
in refugees resettled in the United States (US) [1, 3, 5, 6].
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These infections may be subclinical and can be associated with
substantial morbidity, including anemia, malnutrition, small
bowel obstruction, growth restriction, periportal hypertension,
hyperinfection syndrome and possible cognitive impairment in
children if not treated [2, 6]. In May 1999, the CDC initiated
pre-departure treatment programs for intestinal parasites,
which began with a single dose of Albendazole within 3 days of
departure to the US for all non-pregnant refugees over the age of
2 [4, 5, 7]. In addition to Albendazole, the guidelines expanded
in 2005 to include treatment for Strongyloidiasis (Ivermectin)
in refugees from Asia, the Middle East, and non-Loa Loa
endemic African countries and treatment for Schistosomiasis
(Praziquantel) in refugees from sub-Saharan Africa [4, 5, 7, 8].
Children are a special population because no presumptive antihelminth treatment is recommended in those under 12 months
of age and there are limitations to the use of Praziquantel and
Ivermectin [2, 4, 9]. It is expected that pediatric refugees who
arrive from a refugee camp would be more likely to receive
appropriate pre-departure treatment because they are in a more
controlled setting and as a result of the treatment, less likely to
have intestinal parasites on their intake examinations. However,
it is unclear and not previously documented if the suboptimal
living conditions with close exposure to others from various
regions change the intestinal parasite diaspora in this group [5].
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Table 1 Country of Origin and refugee camp status in Kentucky pediatric
refugees

3584 total
charts

Country of Origin
Dem. Rep. of the Congo
Somalia
Myanmar
Iraq
Bhutan
Syria
Cuba
Afghanistan
Sudan
Burundi
Pakistan
Eritrea
Rwanda
Ethiopia
Sri Lanka
Ukraine
Kenya
Ivory Coast
Saudi Arabia
Tanzania
Lebanon
Thailand
Kuwait
Central African Republic
Ghana
Nepal
North Korea
Turkey
Angola
Iran
Jordan
Total

385 excluded

3199
included
1622
no
refugee camp

1577
refugee camp

Figure 1 Overall review of the Kentucky refugee data included in the
data analysis

The objectives of this study were to characterize and compare
the intestinal parasite infection profiles and pre-departure
treatment of Kentucky pediatric refugees who arrived from
traditional refugee camps with those who did not arrive through
a refugee camp. The authors will also describe the compliance of
pre-departure treatment to the CDC recommendations in this
population.

Methods
In 2012, the Kentucky Office of Refugees, in collaboration with
the University of Louisville Global Health Center, created a
secure database which stored the data from all domestic health
screenings of refugees entering Kentucky. This database was kept
in the REDCap platform (Developed at Vanderbilt University
Institute for Clinical and Translational Research; Nashville, TN)
and maintained by the University of Louisville Global Health
Center. Information pertaining to refugee care, specifically predeparture anti-helminth treatment, prior to entry into the US
is also maintained within the database and is provided directly
from the CDC’s Electronic Disease Network (EDN), which is a
centralized electronic reporting system that notifies US state
and local health departments as well as screening clinics of the
arrival of refugees and immigrants with medical conditions
requiring follow-up [15]. The investigators received permission
from the University of Louisville Institutional Review Board
(IRB) to review charts from the REDCap database for this study.
This is a retrospective, descriptive study of patient charts in
the REDCap database from September 1, 2012 to September
1, 2017. All refugees < 18 years of age and not pregnant at the
time of treatment were included in the analysis of the parasite
profiles. Refugees without any documentation pertaining to
their previous residence within or outside of traditional refugee
camps were excluded from all analyses. In addition, refugees
with known cysticercosis or an unexplained seizure disorder
were excluded through the CDC’s Albendazole-treatment
protocol because of the risk of adverse neurological effects from
a cytocidal agent[4].

Refugee
Camp
628
409
158
5
274
20
0
5
18
28
0
4
11
3
0
0
4
0
0
3
0
2
0
1
1
1
1
1
0
0
0
1577

No Refugee
Camp
239
143
218
371
1
234
242
70
20
3
25
18
4
4
7
7
0
4
4
0
3
0
2
0
0
0
0
0
1
1
1
1622

Total
867
552
376
376
275
254
242
75
38
31
25
22
15
7
7
7
4
4
4
3
3
2
2
1
1
1
1
1
1
1
1
3199

The patient charts were grouped based on the region of the world
from which they originated which was documented in their
immigration/refugee records. The CDC groups the countries
of origin into 3 major regions based on previous epidemiologic
information about the endemic intestinal parasites: Middle
East, Asia, North Africa, Latin America, and the Caribbean
(Region 1); Central and Southern African countries not endemic
for Loa Loa (Region 2); Central and Southern African countries
endemic for Loa Loa (Region 3)[4]. The recommendation for
pre-departure treatment for refugees from Region 1 is single
dose Albendazole and Ivermectin; Region 2 is single dose
Albendazole, Ivermectin, Praziquantel; Region 3 is single
dose Albendazole and Praziquantel [4]. Additionally, the
recommendations consider the safety profile of each medication,
particularly in children. Praziquantel is not recommended for
children < 4 years of age while Ivermectin is not recommended
for children < 15 kilograms(kg). The CDC does not recommend
presumptive therapy in children < 12 months of age [2, 4].
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Figure 2 The distribution of the results of stool studies of Kentucky
pediatric refugees
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Table 2 Types of parasites detected in the stool culture results of
pediatric refugees from the different world regions defined by the CDC
Stool culture results
Blastocystis
Giardia
Giardia, Blastocystis
Other nonpathogenic parasites
Dientamoeba and Blastocystis
Dientamoeba
Entamoeba histolytica
Entamoeba histolytica, Blastocystis
Hymenolepis, Blastocystis
Dientamoeba, Giardia, Blastocystis
Entamoeba histolytica, Giardia
Dientamoeba, Giardia
Entamoeba histolytica, Dientamoeba
Trichuris, Dientamoeba
Strongyloides
Giardia, Blastocystis, Hymenolepis
Dientamoeba, Hymenolepis, Blastocystis
Ascaris, Giardia
Hymenolepis
Tapeworm, Blastocystis
Trichuris
Giardia, Trichuris, Blastocystis
Trichuris, Blastocystis
Giardia, Tapeworm, Blastocystis
Total

Region 1 N (%)
152 (49.8)
55 (18)
17 (5.6)
17 (5.6)
18 (5.9)
15 (4.9)
7 (2.3)
8 (2.6)
3 (1)
3 (1)
3 (1)
1 (0.3)
1 (0.3)
1 (0.3)
1 (0.3)
1 (0.3)
1 (0.3)
1 (0.3)
0
0
0
0
0
0
305

Region 2 N (%)
78 (44.1)
44 (24.9)
24 (13.6)
15 (8.5)
3 (1.7)
3 (1.7)
0
0
3 (1.7)
1 (0.6)
0
1 (0.6)
0
0
0
0
0
0
1 (0.6)
1 (0.6)
0
1 (0.6)
1(0.6)
1(0.6)
177

Region 3 N (%)
117 (59.1)
27 (13.6)
27 (13.6)
13 (6.6)
4 (2)
0
6 (3)
1 (0.5)
0
1 (0.5)
0
0
0
0
0
0
0
0
0
0
1 (0.5)
1 (0.5)
0
0
198

The results of stool cultures were compared between those who
arrived through a refugee camp and those who did not. The 3
regional subgroups were used evaluate potential trends in
parasite diaspora based on region and refugee camp status. The
records were reviewed to determine if the included pediatric
refugees received appropriate pre-departure treatment for
intestinal parasites as outlined by the CDC. Children < 4
years of age were excluded from this analysis because of the
anti-helminth restrictions in the younger and smaller weight
individuals. The stool pathology was described for those who
received appropriate pre-departure treatment and those who
did not. It was further described within the 3 regional groups
and refugee camp status.
A sensitivity analysis was conducted using the refugees < 4 years
of age and < 12 months of age to determine the appropriateness
of treatment and determine if they had different intestinal
parasite profiles compared to those 4 years of age and older. The
descriptive analysis of all the data was performed using IBM
SPSS version 21.

Results
There were 3,584 pediatric refugee charts reviewed from
9/1/2012 to 9/1/2017. 385 were excluded because the records
were missing information about refugee camp stay prior to
immigration into Kentucky, resulting in 3,199 pediatric refugee
records (Figure 1). There were 686 (21.4%) pediatric refugees
< 4 years of age and 57 (1.8%) < 12 months of age. Kentucky
pediatric refugees most commonly came from The Democratic
Republic of the Congo (Table 1).
Upon arrival, there were 1,653 children who had stool studies
results (Figure 2). There were 680 children that had abnormal
stool studies and 426 (62.6%) received pre-departure therapy
prior to arrival in the US. In children who did not spend
any time in a camp and had stool studies, 326 (33.9%) had
intestinal parasites in their stool. In children who spent time in
refugee camps and were tested, 354 (51%) were found to have
parasites in their stool (Figure 2). In children who arrived to
Kentucky from refugee camps and did not receive pre-departure
treatment, the incidence of intestinal parasites was 71 out of 165
(43%).
Overall, pre-departure anti-helminth therapy in refugees > 4
years of age was appropriate based on CDC recommendations

Table 3 Kentucky refugee children who received appropriate antihelminth treatment based on the CDC recommendations prior to arrival
in the United States

Refugee Population

Refugee
camp

No refugee
camp

Total

Region 1. Asia, Middle East, North
Africa, Latin American, & Caribbean

86.7%

80%

83%

Region 2. Sub-Saharan Africa,
non-Loa loa-endemic area

85.4%

56.4%

79.8%

Region 3. Sub-Saharan Africa,
Loa loa– endemic area

22.5%

50.3%

30.2%

Total

61.7%

69.8%

64.7%

64.7% of the time. There were only 6 total cases of soil helminths,
1 case of Strongyloides and no cases of Schistosomiasis. The
most common parasites found in refugee children from all
three regions were Blastocystis and Giardia (Table 2). The
pediatric refugees from this Region 1 were treated based on CDC
guidelines 83% of the time (Table 3). There were 75 patients
who arrived from Afghanistan. None of these patients received
presumptive treatment regardless of refugee camp status and
the most common organisms identified were also Giardia (18%)
and Blastocystis (18%). Ascaris was present in 3% of the Afghani
pediatric refugees.
The pediatric refugees from Region 2 had a 79.8% compliance
rate with CDC guidelines while the pediatric refugees
from Region 3 had 30.2% compliance (Table 3). The CDC
recommends that these individuals from Region 3 should have
Ivermectin added based on the results of stool studies. However,
if children who received all three as presumptive treatment
were included in the “appropriate treatment” category, then
compliance would be 85.5% for region 3 and 83.1% for all
pediatric Kentucky refugees.
These results were further analyzed and grouped into children
who were previously in a refugee camp and those who were not.
Overall, in pediatric refugees previously in a refugee camp, they
received appropriate presumptive intestinal parasite treatment
61.7% of the time (Table 3). The most common parasites
found children previously in refugee camps from each of the
three regions were Blastocystosis and Giardia (Figure 3).
Based on the CDC recommendations by region, the children in
Region 1 had 86.7% compliance, Region 2, 85.4% compliance,
and Region 3, 22.5% compliance (Table 3). If children in
Region 3 who received all three medications were included in
the “appropriate treatment” category, then compliance would
be 88.4% for Region 3 and 86.9% for all pediatric Kentucky
refugees who were previously in refugee camps.
Overall, in pediatric refugees not previously in a refugee camp,
they received appropriate presumptive therapy 69.8% of the
time (Table 3). The most common parasites found in refugee
children not previously in camps from each of the three regions
were Blastocystosis and Giardia (Figure 3). Based on the CDC
recommendations by region, the children in Region 1 had 80%
compliance, Region 2, 56.4% compliance, and Region 3, 50.3%
compliance (Table 3). If children in Region 3 who received all
three medications were included in the “appropriate treatment”
category, then compliance would be 78.3% for Region 3
and 76.7% for all pediatric Kentucky refugees who were not
previously in refugee camps.
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Region 1- refugee camp

Region 1- no refugee camp
Region 1 - no refugee camp

Region 1 - refugee camp

Strongyloides
2%

Other
14%

Other
13%
Giardia
12%

Giardia and
Blastocystis
8%

Blastocystis
66%

Blastocystis
52%

Giardia
28%

Giardia and
Blastocystis
5%

Region 2- no refugee camp

Region 2- refugee camp

Region 2 - no refugee camp

Region 2 - refugee camp

Other
26%
Giardia
9%

Other
10%
Tapeworm,
Blastocystis
4%
Giardia and
Blastocystosis
4%

Blastocystis
57%

Giardia and
Blastocystis
16%

Region 3- no refugee camp

Region 3- refugee camp

Region 3 - no refugee camp

Other
8%

Blastocystis
74%

Giardia
22%

Blastocystis
52%

Region 3 - refugee camp

Other
10%

Giardia
8%
Giardia and
Blastocystis
10%

Blastocystis
58%

Giardia
16%

Giardia and
Blastocystis
16%

Figure 3 The most common intestinal parasites by region and history of refugee camp exposure
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An analysis was conducted looking at pediatric refugees <
4 years of age and < 12 months to determine if they were
inappropriately receiving anti-helminth treatment and if their
stool culture results were different from the remainder of the
charts reviewed. In children < 4 years, pre-departure treatment
was given in 416 patients. There were 37 (8.8%) patients who
received Praziquantel, which is not approved in this group. 32
of these children arrived through a refugee camp. There were
65 refugees < 4 years who were given Ivermectin. 47 (72.3%)
of these patients were under 15 kg and therefore should not
have received it. Seven of the children < 15 kg who received
Ivermectin arrived through a refugee camp. In summary, there
were 20.1% of children who received Praziquantel or Ivermectin
despite contraindications based on age and weight. 46.4% of
these children arrived through a refugee camp.
There were 354 refugees < 4 years who were tested for intestinal
parasites. 92 had positive stool studies on evaluation, 51 of
which received pre-departure treatment. The most common
organisms were Giardia and Blastocystis and there were no
cases of soil helminths, Schistosomiasis, or Strongyloides.
There were 11 (17.4%) refugee children < 12 months of age
who received pre-departure treatment for intestinal parasites
despite the CDC recommendations. Forty (of the total 63)
children < 12 months of age were tested for intestinal parasites
and 3 had positive stool cultures, which resulted Giardia and/
or Blastocystis. None of the 3 refugee children < 12 months
of age who had positive stool cultures received pre-departure
treatment.

Discussion
The current CDC guidelines for pre-departure treatment of
intestinal parasites in refugees were designed to specifically
address infections with soil transmitted helminths,
Strongyloides, and Schistosomiases. This study supports the
findings of other numerous studies performed on refugees
resettling in other US and Western cities which demonstrate
a low incidence of infection with these parasites while also
demonstrating the persistent burden of protozoal infections,
specifically Giardia and Blastocystis [4, 5, 10, 11].
The distinction between prior living environments (refugee
camp vs none) has been used to explain differences in health
profiles of newly arriving refugee children, however differences
in intestinal parasite burden and pre-treatment medications
has not been evaluated prior to this study [12]. This study
demonstrated similar stool parasite profiles in pediatric
refugees regardless of prior encampment status and country
of origin; however, those arriving directly from refugee camps
presented with higher rates of positive stool results. This is
likely attributed to irregular access to preventive health services,
insufficient sanitation facilities and hygiene practices, and
higher likelihood of transmission rates of communicable illness
particularly among children living in poor housing and close
quarters conditions [12].
Children who arrived through refugee camps had a lower
compliance with CDC recommendations for pre-departure
therapy compared to those who did not arrive through refugee
camps; however, this appears to be skewed by Region 3.
Refugees arriving through camps from Regions 1 and 2 had a

high compliance with CDC recommendations with appropriate
pre-departure treatment rates of 86.7% and 85.4% respectively,
while Region 3 compliance was low. The guidelines recommend
refugees from Region 3 receive Albendazole and Praziquantel
but many of the Kentucky pediatric refugees received tripletherapy with Albendazole, Praziquantel, and Ivermectin [4].
While overtreatment in this group should not increase parasite
burden as identified by stool studies, it unnecessarily increases
the risk of encephalopathy associated with a high load of dying
microfilaria in an established Loa Loa endemic region [4, 9].
Therefore, the CDC guidelines should be more closely adhered
to in this group of individuals as originally designed. Based
on these findings, education initiatives focused on health care
workers working in refugee camps located in countries endemic
for Loa Loa are recommended to improve the adherence to the
CDC guidelines for pre-departure parasite treatment.
This study additionally found that there was inappropriate predeparture treatment of young children. 86% of the children <
4 years of age who received Praziquantel and 14.9% of children
< 15 kg who received Ivermectin arrived through a refugee
camp. The American Academy of Pediatrics warns against the
use of Ivermectin in children under 2 years of age and under
15 kg because they have a less developed blood brain barrier
and therefore have a higher risk of central nervous system
side effects, namely encephalopathy [9]. The culture results
in children < 4 and those < 12 months are similar to children
in the overall study population and didn’t show an increase
in soil helminths, Strongyloides, or Schistosomiasis in the
children who did not receive pre-departure therapy. These
findings further support the need to improve adherence to the
guidelines set forth by the CDC, through awareness, education,
and treatment coordination among refugee camp healthcare
workers, since presumptive therapy will not provide any added
benefit in these populations but will increase the number of
possible adverse effects.
This study showed Giardia and Blastocystis as the major stool
pathogens in Kentucky pediatric refugees. It has been debated
whether Blastocystis is a pathogenic organism; however, some
suggest to treat if a patient is symptomatic and has no other
identifiable organism in the stool [13]. Giardia can cause
diarrhea, malaise, abdominal cramping, nausea, weight loss,
and failure to thrive [9]. At this time, treatment of symptomatic
individuals is recommended to prevent infection and hasten the
resolution of symptoms; however, the illness is typically selflimiting. Currently, the stool of pediatric Kentucky refugees
is only tested if symptomatic and therefore would warrant
treatment. There are many individuals who are asymptomatic
and have Giardia in their stool. These patients only require
treatment if there is an increased risk of transmission to others
[9, 14]. This includes children who attend daycare/school, live
at home with an immunocompromised individual, live at home
with a pregnant woman, or handle food [9]. Unfortunately,
many of the Kentucky pediatric refugees will fall into this
group and require treatment even if they are asymptomatic.
Albendazole daily for 5 days or Metronidazole 3 times daily
for five days can be used to treat Giardia infections in any age
individual [14]. Although Albendazole is more convenient at
once daily, Metronidazole is a more cost-effective treatment
in the US. In addition, Metronidazole would be an appropriate
treatment for Blastocystis in the setting of symptomatic illness
and absence of other causative organisms [13].
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The authors recommend the initiation of treatment with
Metronidazole promptly in symptomatic refugee children who
have received appropriate pre-departure treatment. Screening
studies can take several days to weeks and this would provide
antimicrobial coverage for Giardia and Blastocystis and
therefore, prevent the spread of infection in a population where
follow up and language barriers can challenge the provision of
appropriate treatment and healthcare.

2.

3.

4.
The data for this study were obtained through a database review,
therefore a limitation of the study is incorrectly inputted data
into REDCap. However, a large number of charts were reviewed
to offset any effect of random human error and all data gathered
from pre-departure health assessments were provided directly
from the CDC’s EDN, which is unlikely to have incorrectly
inputted data [15]. Another limitation is the lack of follow up
information for those patients who had positive stool results.
Because the database captured intake data, it does not have
information about the treatment and follow up in those children
with positive stool studies. Additionally, stool ova and parasite
testing have low sensitivity for many intestinal parasites,
especially if only one or two samples were submitted, therefore
our measurement of parasite burden likely underestimates the
true prevalence of intestinal parasites within our clinical samples.
Lastly, refugees provided stool studies if they were symptomatic
upon arrival or if they presented to their initial screening visits
with incomplete records of pre-departure treatment. Therefore,
we cannot evaluate the positive predictive value of stool testing
in our study population as we cannot differentiate those who
underwent stool studies due to symptoms and those who did
not present with adequate information to their initial screening
visit.

5.

6.

7.

8.

9.

10.
In conclusion, there is high compliance to the CDC
recommendations for presumptive treatment of intestinal
parasites in Kentucky pediatric refugees from Regions 1 and 2.
Refugees from region 3 are inappropriately given Ivermectin
which can cause encephalopathy in patients in this high risk
group and interventions should be focused on improving
compliance with CDC recommendations in this group and in
young children (< 4 years). Early initiation of Metronidazole in
symptomatic pediatric refugees should be considered to prevent
the spread of protozoal infection upon resettlement.
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